dc.contributor.author | Nowotny, Hanna | |
dc.contributor.author | Neumann, Uta | |
dc.contributor.author | Tardy-Guidollet, Veronique | |
dc.contributor.author | Faisal Ahmed, Ahmed | |
dc.contributor.author | Baronio, Federico | |
dc.contributor.author | Battelino, Tadej | |
dc.contributor.author | Bertherat, Jerome | |
dc.contributor.author | Blankenstein, Oliver | |
dc.contributor.author | Bonomi, Marco | |
dc.contributor.author | Bouvattier, Claire | |
dc.contributor.author | De la Perrière, Aude Brac | |
dc.contributor.author | Brucker, Sara | |
dc.contributor.author | Cappa, Marco | |
dc.contributor.author | Chanson, Philippe | |
dc.contributor.author | Van der Grinten, Hedi L. Claahsen | |
dc.contributor.author | Colao, Annamaria | |
dc.contributor.author | Cools, Martine | |
dc.contributor.author | Davies, Justin H. | |
dc.contributor.author | Dorr, Helmut-Gunther | |
dc.contributor.author | Fenske, Wiebke K. | |
dc.contributor.author | Ghigo, Ezio | |
dc.contributor.author | Giordano, Roberta | |
dc.contributor.author | Gravholt, Claus H. | |
dc.contributor.author | Huebner, Angela | |
dc.contributor.author | Husebye, Eystein Sverre | |
dc.contributor.author | Igbokwe, Rebecca | |
dc.contributor.author | Juul, Anders | |
dc.contributor.author | Kiefer, Florian W. | |
dc.contributor.author | Leger, Juliane | |
dc.contributor.author | Menassa, Rita | |
dc.contributor.author | Meyer, Gesine | |
dc.contributor.author | Neocleous, Vassos | |
dc.contributor.author | Phylactou, Leonidas A. | |
dc.contributor.author | Rohayem, Julia | |
dc.contributor.author | Russo, Gianni | |
dc.contributor.author | Scaroni, Carla | |
dc.contributor.author | Touraine, Philippe | |
dc.contributor.author | Unger, Nicole | |
dc.contributor.author | Vojtkova, Jarmila | |
dc.contributor.author | Yeste, Diego | |
dc.contributor.author | Lajic, Svetlana | |
dc.contributor.author | Reisch, Nicole | |
dc.date.accessioned | 2022-10-05T14:10:21Z | |
dc.date.available | 2022-10-05T14:10:21Z | |
dc.date.created | 2022-05-15T18:49:15Z | |
dc.date.issued | 2022 | |
dc.identifier.issn | 0804-4643 | |
dc.identifier.uri | https://hdl.handle.net/11250/3024123 | |
dc.description.abstract | Objective: To assess the current medical practice in Europe regarding prenatal dexamethasone (Pdex) treatment of congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency.
Design and methods: A questionnaire was designed and distributed, including 17 questions collecting quantitative and qualitative data. Thirty-six medical centres from 14 European countries responded and 30 out of 36 centres were reference centres of the European Reference Network on Rare Endocrine Conditions, EndoERN.
Results: Pdex treatment is currently provided by 36% of the surveyed centres. The treatment is initiated by different specialties, that is paediatricians, endocrinologists, gynaecologists or geneticists. Regarding the starting point of Pdex, 23% stated to initiate therapy at 4–5 weeks postconception (wpc), 31% at 6 wpc and 46 % as early as pregnancy is confirmed and before 7 wpc at the latest. A dose of 20 µg/kg/day is used. Dose distribution among the centres varies from once to thrice daily. Prenatal diagnostics for treated cases are conducted in 72% of the responding centres. Cases treated per country and year vary between 0.5 and 8.25. Registries for long-term follow-up are only available at 46% of the centres that are using Pdex treatment. National registries are only available in Sweden and France.
Conclusions: This study reveals a high international variability and discrepancy in the use of Pdex treatment across Europe. It highlights the importance of a European cooperation initiative for a joint international prospective trial to establish evidence-based guidelines on prenatal diagnostics, treatment and follow-up of pregnancies at risk for CAH. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Bioscientifica | en_US |
dc.rights | Navngivelse 4.0 Internasjonal | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/deed.no | * |
dc.title | Prenatal dexamethasone treatment for classic 21-hydroxylase deficiency in Europe | en_US |
dc.type | Journal article | en_US |
dc.type | Peer reviewed | en_US |
dc.description.version | publishedVersion | en_US |
dc.rights.holder | Copyright 2022 the authors | en_US |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 2 | |
dc.identifier.doi | 10.1530/EJE-21-0554 | |
dc.identifier.cristin | 2024710 | |
dc.source.journal | European Journal of Endocrinology (EJE) | en_US |
dc.source.pagenumber | K17-K24 | en_US |
dc.identifier.citation | European Journal of Endocrinology (EJE). 2022, 168 (5), K17-K24. | en_US |
dc.source.volume | 168 | en_US |
dc.source.issue | 5 | en_US |